We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC).
We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab after chemotherapy between March 2018 and December 2021. Patients were divided according to BMI into the non-overweight group (BMI <25 kg/m2) and the overweight group (BMI ≥25 kg/m2). We compared the two groups' tumour response, survival rates, and incidence of immune-related adverse events (irAEs) and investigated the factors predicting survival.
Of 84 eligible patients, 63 (75%) and 21 (25%) were in the non-overweight and overweight groups, respectively. Although the objective response rate was higher in the overweight group (55%) than that in the non-overweight group (29%), the difference was not significant. Progression-free survival (PFS) was significantly longer in the overweight group (median 15.2 months) than that in the non-overweight group (median 4.8 months; p=0.01). Overall survival was also longer in the overweight group (median 36.1 months) compared to that in the non-overweight group (13.4 months), but the difference was not significant (p=0.11). Multivariable analysis showed that overweight was significantly associated with favourable PFS. Any and severe (grade 3) irAEs were observed in 15 (24%) and 5 (7.9%) patients in the non-overweight group, respectively, and in 8 (38%) and 2 (9.5%) patients in the overweight group, respectively, but the differences were not significant.
BMI was associated with oncological outcomes in patients with advanced UC who received pembrolizumab but not with the development of irAEs.
Anticancer research. 2023 Jan [Epub]
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna, Shuji Harada, Hiroomi Matsumoto, Soichiro Akasaka, Yujiro Nagata, Akinori Minato, Ken-Ichi Harada, Naohiro Fujimoto
Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; ., Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan., Department of Urology, Kokura Memorial Hospital, Kitakyushu, Japan., Department of Urology, Munakata Suikokai General Hospital, Fukutsu, Japan., Department of Urology, Shin-kokura Hospital, Kitakyushu, Japan., Department of Urology, Shin-yukuhashi Hospital, Yukuhashi, Japan., Department of Urology, Kitakyushu City Yahata Hospital, Kitakyushu, Japan., Department of Urology, Moji Medical Centre, Kitakyushu, Japan.